SlideShare a Scribd company logo
Dr. Mahmoud H. Taleb
Assistant Professor of Pharmacology and Toxicology
Head of Department of Pharmacology and Medical Sciences,
Faculty of Pharmacy- Al azhar University
The Autonomic Nervous System
Adrenergic SystemAdrenergic System
• Adrenergic neurons release norepinephrine as the
primary neurotransmitter.
• These neurons are found in the central nervous system
(CNS) and also in the sympathetic nervous system, where
they serve as links between ganglia and the effector
organs.
• The adrenergic neurons and receptors, located either
presynaptically on the neuron or postsynaptically on the
effector organ, are the sites of action of the adrenergic
drugs.
THE ADRENERGIC NEURON
2- Sympathetic nervouS SyStem
 Sympathetic Nervous System (adrenergic)
Norepinephrine = neurotransmitter
- Drugs that mimic = adrenergic drugs,
sympathomimetics, or adrenomemetics
* Adrenergic agonists - Drugs initiate a
response
- Drugs that block = adrenergic blockers, sympatholytics
or adrenolytics
* Adrenergic antagonists - prevent a response
Dr. Mahmoud H. Taleb 3
Dr. Mahmoud H. Taleb 4
Adrenergic Agonists
The adrenergic drugs affect receptors that are stimulated by
norepinephrine or epinephrine. Some adrenergic drugs act
directly on the adrenergic receptor (adrenoceptor) by
activating it and are said to be sympathomimetic. Others,
which will be dealt with in, block the action of the
neurotransmitters at the receptors (sympatholytics), .
Agonist affinity of α :
-Adrenalin < Noradrenalin <
isoproterenol
-Antagonist : phenoxybenzamine
-IP3/DAG , cAMP ↓and k+ channel
opening.
Agonist affinity of β :
-Iso < Adrenalin < Noradrenalin
-Propraolol
-cAMP and Ca +2 channel opening.
Where are the adrenergic receptors?
Dr. Mahmoud H. Taleb 8
-D1-receptors are postsynaptic receptors located in
blood vessels and CNS.
- D2-receptors are presynaptic present in CNS ,
ganglia, renal cortex.
SYNTHESIS AND RELEASE OF NOREPINEPHRINE
FROM THE ADRENERGIC NEURON
1. The amino acid tyrosine is transported into the sympathetic nerve axon.
2. Tyrosine (Tyr) is converted to DOPA by tyrosine hydroxylase (rate-limiting step for NE
synthesis).
3. DOPA is converted to dopamine (DA) by DOPA decarboxylase.
4. Dopamine is transported into vesicles then converted to norepinephrine (NE) by dopamine β-
hydroxylase (DBH); transport into the vesicle can by blocked by the drug reserpine.
5. An action potential traveling down the axon depolarizes the membrane and causes calcium to
enter the axon.
6. Increased intracellular calcium causes the vesicles to migrate to the axonal membrane and
fuse with the membrane, which permits the NE to diffuse out of the vesicle into
the extracellular (junctional) space. DBH, and depending on the nerve other
secondary neurotransmitters (e.g., ATP), is released along with the NE.
7. The NE binds to the postjunctional receptor and stimulates the effector
organ response
1. Most (~90%) of the NE is transported back into the nerve terminal by a
neuronal reuptake transport system. This transporter is blocked by cocaine;
therefore, cocaine increases junctional NE concentrations by blocking its
reuptake and subsequent metabolism. (This is a major mechanism by which
cocaine stimulates cardiac function and raises blood pressure.)
2. Some of the junctional NE diffuses into capillaries and is carried out of the
tissue by the circulation. Therefore, high levels of sympathetic activation in
the body increase the plasma concentration of NE and its metabolites.
3. Some of the junctional NE is metabolized within the extracellular space before
reaching the capillaries.
4. A small amount of NE (~5%) is taken up by the postjunctional
tissue (termed "extraneuronal uptake") and metabolized.
NE (and epinephrine) is
metabolized by catechol-O-
methytransferase (COMT) and
monoamine oxidase (MAO).
The final product of these
pathways is vanillylmandelic acid
(VMA).
This final product, along with its
precursors normetanephrine and
metanephrine, is measured in
urine and plasma in the diagnosis
of pheochromocytoma, which can
cause severe hypertension and
cardiac arrhythmias.
Dr. Mahmoud H. Taleb 15
• Sympathomimetic amines that contain the 3,4-dihydroxybenzene group:
(such as epinephrine, norepinephrine, isoproterenol, and dopamine)
are called catecholamines.
• These compounds share the following properties:
1. High potency
2. Rapid inactivation
3. Poor penetration into
the CNS
Dr. Mahmoud H. Taleb 18
A. Catecholamines
Sympathomimetic amines that contain the 3,4-dihydroxybenzene group (such
as epinephrine, norepinephrine, isoproterenol, and
dopamine) are called catecholamines. These compounds share the
following properties:
High potency: Drugs that are catechol derivatives (with OH groups in the 3
and 4 positions on the benzene ring) show the highest potency in directly
activating α or β receptors
Rapid inactivation: Not only are the catecholamines metabolized by COMT
postsynaptically and by MAO intraneuronally, they are also metabolized in
other tissues. For example, COMT is in the gut wall, and MAO is in
the liver and gut wall. Thus, catecholamines have only a brief period of action
when given parenterally, and they are ineffective when administered orally
because of inactivation2.
Poor penetration into the CNS: Catecholamines are polar and, therefore, do
not readily penetrate into the CNS. Nevertheless, most of these drugs have
some clinical effects (anxiety, tremor, and headaches) that are attributable
to action on the CNS.
Dr. Mahmoud H. Taleb 19
B. Noncatecholamines
Compounds lacking the catechol hydroxyl groups
have longer half-lives, because they are not
inactivated by COMT. These include phenylephrine,
ephedrine, and amphetamine. Phenylephrine, an
analog of epinephrine, has only a single OH at
position 3 on the benzene ring, whereas ephedrine
lacks hydroxyls on the ring but has a methyl
substitution at the α-carbon. These are poor
substrates for MAO and, thus, show a prolonged
duration of action, because MAO is an important
route of detoxification. Increased lipid solubility of
many of the noncatecholamines permits greater
access to the CNS.
• Compounds lacking the catechol hydroxyl groups
have longer half-lives, because they are not
inactivated by COMT.
• These include:
 phenylephrine,
 ephedrine, and
 amphetamine.
• Epinephrine is synthesized from
tyrosine in the adrenal medulla and
released, along with small quantities of
norepinephrine, into the bloodstream.
• Epinephrine interacts with both α and
β receptors.
• At low doses, β effects (vasodilation)
on the vascular system predominate,
whereas at high doses, α effects
(vasoconstriction) are strongest.
• Adrenaline is a catecholamine, produced only by
the adrenal glands from the amino acid,
phenylalanine and tyrosine. That acts as both a
neurotransmitter and hormone is also known as
(epinephrine).
• Adrenaline is produced in the medulla of the
adrenal glands and in some neurons of the central
nervous system. They are released into the
bloodstream and serve as chemical mediators, and
also convey the nerve impulses to various organs.
Adrenaline has many different actions depending on the type
of cells it is acting upon. However, the overall effect of
adrenaline is to prepare the body for the ‘fight or flight’
response in times of stress, i.e., for vigorous and/or sudden
action. Key actions of adrenaline include increasing the heart
rate, increasing blood pressure, expanding the air passages
of the lungs, enlarging the pupil in the eye (mydriasis),
redistributing blood to the muscles and altering the body’s
metabolism, so as to maximise blood glucose levels
(primarily for the brain).
Adrenaline interacts with both α and β receptors. At low
doses, β effects (vasodilation) on the vascular system
predominate, whereas at high doses, α effects
(vasoconstriction) are the strongest.
CARDIOVASCULAR RESPIRATORY HYPERGLYCEMIA LIPOLYSIS
Epinephrine strengthens
the contractility of the
myocardium (positive
inotropic: β1 action) and
increases its rate of
contraction (positive
chronotropic: β1 action).
Epinephrine causes
powerful
bronchodilation by
acting directly on
bronchial smooth
muscle (β2 action).
Epinephrine has a
significant
hyperglycemic effect
because of increased
glycogenolysis in the
liver (β2 effect),
increased release of
glucagon (β2 effect), and
a decreased release of
insulin (α2 effect).
Epinephrine initiates
lipolysis through its
agonist activity on the β
receptors of adipose
tissue, which upon
stimulation activate
adenylyl cyclase to
increase cAMP levels.
•ACTIONS OF ADRENALINE
• HERT :
• Beta-1 mediated action - Powerful Cardiac stimulant ( +ve chronotropic, +ve
inotropic)
• Acts on beta-1 receptors in myocardium, pacemaker cells and conducting tissue
– Heart rate increases by increasing slow diastolic depolarization of cells in SAN
– High doses cause marked rise in heart rate and BP causing reflex depression of
SAN – unmasking of latent pacemaker cells in AVN and PF – arrhythmia.
– Cardiac systole is shorter and more powerful
– Cardiac output is enhanced and Oxygen consumption is increased
– Cardiac efficiency is markedly decreased
• Conduction velocity in AVN, atrial muscle fiber, ventricular fibre and Bundle of His
increased – benefit in partial AV block
– Reduced refractory period in all cardiac cells
•
• Blood Vessels :
• Seen mainly in the smaller vessels – arterioles
– Vasoconstriction (alpha) and vasodilatation
(beta) .
• Decreased blood flow to skin and mucus
membranes and renal beds – alpha effect (1
and 2)
• Increased blood flow to skeletal muscles,
coronary and liver vessels - (Beta-2 effect)
counterbalanced by vasoconstrictor effect of
alpha receptors.
• 
• Respiratory :
– Powerful bronchodilator
– Relaxes bronchial smooth muscle (not NA)
• Beta-2 mediated effect
• Physiological antagonist to mediators of
bronchoconstriction e.g. Histamine
• GIT :
• Relaxation of gut muscles (alpha and beta
effect) and constricted sphincters – reduced
peristalsis – not clinical importance.
• Uterus :
• Adrenaline contracts and relaxes Uterus
(alpha and beta action) but net effect depends
on status of uterus and species – pregnant
relaxes but non-pregnant – contracts.
• Skeletal Muscle :
– Facilitation of Ach release in NM junction (α -1).
– Beta-2 acts directly on Muscle fibres.
– Abbreviated active state and less tension in slow
conducting fibres and enhanced muscle spindle
firing – tremor.
• Hyperglycemia :
• Epinephrine has a significant hyperglycemic
effect because of increased glycogenolysis in
the liver (β2 effect),increased release of
glucagon (β2 effect), and a decreased release
of insulin (α2 effect).
• Lipolysis :
• Epinephrine initiates lipolysis through agonist
activity on the β receptors of adipose tissue.
Increased levels of cAMP stimulate a
hormone-sensitive lipase, which hydrolyzes
triglycerides to free fatty acids and glycerol.
• Metabolic effects :
• Increases concentration of glucose and lactic acid
• Calorigenesis (β-2 and β-3)
• Inhibits insulin secretion (α-2)
• Decreases uptake of glucose by peripheral tissue
• Simulates glycogenolysis - Beta effect
• Increases free fatty acid concentration in blood
• Hypokalemia – initial hyperkalemia
BRONCHOSPASM GLAUCOMA ANAPHYLACTIC
SHOCK
CARDIAC ARREST ANESTHETICS
Epinephrine is the
primary drug used in
the emergency
treatment of any
condition of the
respiratory tract
when
bronchoconstriction
has resulted in
diminished
respiratory
exchange.
In ophthalmology,
a two-percent
epinephrine
solution may be
used topically to
reduce
intraocular
pressure in open-
angle glaucoma.
Epinephrine is the
drug of choice for
the treatment of
Type I
hypersensitivity
reactions in
response to
allergens.
Epinephrine may
be used to restore
cardiac rhythm in
patients with
cardiac arrest
regardless of the
cause.
The effect of the
drug is to greatly
increase the
duration of the
local anesthesia.
• Because norepinephrine is the
neuromediator of adrenergic nerves, it
should theoretically stimulate all types of
adrenergic receptors.
• In practice, when the drug is given in
therapeutic doses to humans, the α-
adrenergic receptor is most affected.
VASOCONSTRICTION BARORECEPTOR REFLEX EFFECTS OF ATROPINE PRE-
TREATMENT
Norepinephrine causes a rise in
peripheral resistance due to
intense vasoconstriction of most
vascular beds, including the
kidney (α1 effect).
In isolated cardiac tissue,
norepinephrine stimulates
cardiac contractility; however, in
vivo, little if any cardiac
stimulation is noted.
If atropine, which blocks the
transmission of vagal effects, is
given before norepinephrine,
then norepinephrine stimulation
of the heart is evident as
tachycardia.
• Isoproterenol is a direct-acting
synthetic catecholamine that
predominantly stimulates both
β1- and β2-adrenergic receptors.
• Its nonselectivity is one of its
drawbacks and the reason why it
is rarely used therapeutically.
• Its action on α receptors is
insignificant.
CARDIOVASCULAR PULMONARY OTHER EFFECTS
Isoproterenol produces
intense stimulation of the
heart to increase its rate and
force of contraction, causing
increased cardiac output.
Isoproterenol is as active as
epinephrine and rapidly
alleviates an acute attack of
asthma when taken by
inhalation (which is the
recommended route).
Other actions on β
receptors, such as increased
blood sugar and increased
lipolysis, can be
demonstrated but are not
clinically significant.
• Dopamine, the immediate metabolic
precursor of norepinephrine, occurs
naturally in the CNS in the basal ganglia,
where it functions as a neurotransmitter, as
well as in the adrenal medulla.
• Dopamine can activate α- and β-adrenergic
receptors.
CARDIOVASCULAR RENAL & VISCERAL
Dopamine exerts a stimulatory effect on the
β1 receptors of the heart, having both
inotropic and chronotropic effects.
Dopamine dilates renal and splanchnic
arterioles by activating dopaminergic
receptors, thus increasing blood flow to the
kidneys and other viscera.
Therefore, dopamine is clinically useful in
the treatment of shock, in which significant
increases in sympathetic activity might
compromise renal function.
• Dobutamine is a synthetic, direct-acting
catecholamine that is a β1-receptor agonist.
• One of the stereoisomers has a stimulatory
activity.
• It increases cardiac rate and output with few
vascular effects.
• Dobutamine is used to increase cardiac
output in congestive heart failure as well as
for inotropic support after cardiac surgery.
• Oxymetazoline is a direct-acting
synthetic adrenergic agonist that
stimulates both α1- and α2-adrenergic
receptors.
• It is primarily used locally in the eye or
the nose as a vasoconstrictor.
• Oxymetazoline is found in many over-
the-counter short-term nasal spray
decongestant products as well as in
ophthalmic drops for the relief of redness
of the eyes associated with swimming,
colds, or contact lens.
• Phenylephrine is a direct-acting, synthetic
adrenergic drug that binds primarily to α
receptors and favors α1 receptors over α2
receptors.
• It is not a catechol derivative and,
therefore, not a substrate for COMT.
• Phenylephrine is a vasoconstrictor that
raises both systolic and diastolic blood
pressures.
• Methoxamine is a direct-acting, synthetic adrenergic drug
that binds primarily to α-receptors, with α1 receptors favored
over α2 receptors.
• Methoxamine raises blood pressure by stimulating α1
receptors in the arterioles, causing vasoconstriction.
• This causes an increase in total peripheral resistance.
• Clonidine is an α2 agonist that is used in
essential hypertension to lower blood pressure
because of its action in the CNS.
• It can be used to minimize the symptoms that
accompany withdrawal from opiates or
benzodiazepines.
• Clonidine acts centrally to produce inhibition of
sympathetic vasomotor centers, decreasing
sympathetic outflow to the periphery.
• Albuterol, pirbuterol, and terbutaline are short-
acting β2 agonists used primarily as bronchodilators
and administered by a metered-dose inhaler.
• Salmeterol and formoterol are β2-adrenergic selective, long-
acting bronchodilators.
• Salmeterol and formoterol are the agents of choice for
treating nocturnal asthma in symptomatic patients taking
other asthma medications.
• The marked central stimulatory action of
amphetamine is often mistaken by drug
abusers as its only action.
• The CNS stimulant effects of amphetamine and
its derivatives have led to their use for treating
hyperactivity in children, narcolepsy, and
appetite control.
• Its use in pregnancy should be avoided because
of adverse effects on development of the fetus.
• Tyramine is not a clinically useful
drug, but it is important because it is
found in fermented foods, such as ripe
cheese and Chianti wine.
• It is a normal by-product of tyrosine
metabolism.
• Normally, it is oxidized by MAO in the
gastrointestinal tract, but if the
patient is taking MAO inhibitors, it can
precipitate serious vasopressor
episodes.
• Cocaine is unique among local anesthetics in having
the ability to block the Na+
/K+
-activated ATPase
(required for cellular uptake of norepinephrine) on the
cell membrane of the adrenergic neuron.
• Like amphetamines, it can increase blood pressure by
α-agonist actions and β-stimulatory effects.
• Ephedrine, and pseudoephedrine are plant
alkaloids, that are now made synthetically.
• These drugs are mixed-action adrenergic
agents.
• They not only release stored norepinephrine
from nerve endings but also directly
stimulate both α and β receptors.
• Thus, a wide variety of adrenergic
actions ensue that are similar to those
of epinephrine, although less potent.
• Ephedrine enhances contractility and improves motor
function in myasthenia gravis.
• Ephedrine has been used to treat asthma, as a nasal
decongestant (due to its local vasoconstrictor action), and to
raise blood pressure.
• Pseudoephedrine is primarily used to treat nasal and sinus
congestion or congestion of the eustachian tubes.
Dr. Mahmoud H. Taleb 55

More Related Content

What's hot

Adrenergic agonists
Adrenergic agonistsAdrenergic agonists
Adrenergic agonistsLeul Mesfin
 
Acetylcholine 2018
Acetylcholine 2018Acetylcholine 2018
Acetylcholine 2018BMCStudents
 
Adrenergic neurotransmission
Adrenergic neurotransmissionAdrenergic neurotransmission
Adrenergic neurotransmissionMANISH mohan
 
Neuromuscular blocker
Neuromuscular blockerNeuromuscular blocker
Neuromuscular blockerOmkumar Patel
 
Anticholinesterases
AnticholinesterasesAnticholinesterases
AnticholinesterasesKanav Bhanot
 
Sympathomimitic drugs (Epinephrine & Nor-epinephrine)
Sympathomimitic drugs (Epinephrine & Nor-epinephrine)Sympathomimitic drugs (Epinephrine & Nor-epinephrine)
Sympathomimitic drugs (Epinephrine & Nor-epinephrine)Naimur Rahman Afid
 
Adrenergic Drugs II
Adrenergic Drugs IIAdrenergic Drugs II
Adrenergic Drugs IIcoolboy101pk
 
Adrenergic drugs - pharmacology
Adrenergic drugs - pharmacology Adrenergic drugs - pharmacology
Adrenergic drugs - pharmacology Areej Abu Hanieh
 
UNIT II SYMPATHOLYTIC AGENTS
UNIT II SYMPATHOLYTIC AGENTSUNIT II SYMPATHOLYTIC AGENTS
UNIT II SYMPATHOLYTIC AGENTSSONALI PAWAR
 
Acetylcholine - A neurotransmitter
Acetylcholine - A neurotransmitterAcetylcholine - A neurotransmitter
Acetylcholine - A neurotransmitterSanchit Dhankhar
 
BIOSYNTHESIS OF ACETYLCHOLINE IN CNS AND CHOLINERGIC TRANSMISSION
BIOSYNTHESIS OF ACETYLCHOLINE IN CNS AND CHOLINERGIC TRANSMISSIONBIOSYNTHESIS OF ACETYLCHOLINE IN CNS AND CHOLINERGIC TRANSMISSION
BIOSYNTHESIS OF ACETYLCHOLINE IN CNS AND CHOLINERGIC TRANSMISSIONWasiu Adeseji
 
Local anesthetics pharmacology
Local anesthetics pharmacologyLocal anesthetics pharmacology
Local anesthetics pharmacologyPranatiChavan
 
Acetylcholine
AcetylcholineAcetylcholine
AcetylcholineWali Khan
 
Cholinergic receptors and its modulators(agonists, antagonists etc)
Cholinergic receptors and its modulators(agonists, antagonists etc)Cholinergic receptors and its modulators(agonists, antagonists etc)
Cholinergic receptors and its modulators(agonists, antagonists etc)Asif Hussain
 
Adrenergic antagonists
Adrenergic antagonistsAdrenergic antagonists
Adrenergic antagonistskencha swathi
 

What's hot (20)

Antiarrhythmic agent
Antiarrhythmic agentAntiarrhythmic agent
Antiarrhythmic agent
 
Adrenergic agonists
Adrenergic agonistsAdrenergic agonists
Adrenergic agonists
 
Acetylcholine 2018
Acetylcholine 2018Acetylcholine 2018
Acetylcholine 2018
 
Adrenergic neurotransmission
Adrenergic neurotransmissionAdrenergic neurotransmission
Adrenergic neurotransmission
 
Neuromuscular blocker
Neuromuscular blockerNeuromuscular blocker
Neuromuscular blocker
 
Anticholinesterases
AnticholinesterasesAnticholinesterases
Anticholinesterases
 
Sympathomimitic drugs (Epinephrine & Nor-epinephrine)
Sympathomimitic drugs (Epinephrine & Nor-epinephrine)Sympathomimitic drugs (Epinephrine & Nor-epinephrine)
Sympathomimitic drugs (Epinephrine & Nor-epinephrine)
 
Adrenergic Drugs II
Adrenergic Drugs IIAdrenergic Drugs II
Adrenergic Drugs II
 
Adrenergic drugs - pharmacology
Adrenergic drugs - pharmacology Adrenergic drugs - pharmacology
Adrenergic drugs - pharmacology
 
UNIT II SYMPATHOLYTIC AGENTS
UNIT II SYMPATHOLYTIC AGENTSUNIT II SYMPATHOLYTIC AGENTS
UNIT II SYMPATHOLYTIC AGENTS
 
Acetylcholine - A neurotransmitter
Acetylcholine - A neurotransmitterAcetylcholine - A neurotransmitter
Acetylcholine - A neurotransmitter
 
BIOSYNTHESIS OF ACETYLCHOLINE IN CNS AND CHOLINERGIC TRANSMISSION
BIOSYNTHESIS OF ACETYLCHOLINE IN CNS AND CHOLINERGIC TRANSMISSIONBIOSYNTHESIS OF ACETYLCHOLINE IN CNS AND CHOLINERGIC TRANSMISSION
BIOSYNTHESIS OF ACETYLCHOLINE IN CNS AND CHOLINERGIC TRANSMISSION
 
Local anesthetics pharmacology
Local anesthetics pharmacologyLocal anesthetics pharmacology
Local anesthetics pharmacology
 
Acetylcholine
AcetylcholineAcetylcholine
Acetylcholine
 
Cholinergic receptors and its modulators(agonists, antagonists etc)
Cholinergic receptors and its modulators(agonists, antagonists etc)Cholinergic receptors and its modulators(agonists, antagonists etc)
Cholinergic receptors and its modulators(agonists, antagonists etc)
 
Adrenergic antagonists
Adrenergic antagonistsAdrenergic antagonists
Adrenergic antagonists
 
Pharmacology I Drugs acting on CVS
Pharmacology I  Drugs acting on CVS Pharmacology I  Drugs acting on CVS
Pharmacology I Drugs acting on CVS
 
Antiarrhythmics
AntiarrhythmicsAntiarrhythmics
Antiarrhythmics
 
cholinergic receptors
cholinergic receptorscholinergic receptors
cholinergic receptors
 
Sympathomimetic
SympathomimeticSympathomimetic
Sympathomimetic
 

Similar to 5.adrenergic drugs

Sympathomimetics or Adrenergic Agonists (Introduction, Classification, Adenor...
Sympathomimetics or Adrenergic Agonists (Introduction, Classification, Adenor...Sympathomimetics or Adrenergic Agonists (Introduction, Classification, Adenor...
Sympathomimetics or Adrenergic Agonists (Introduction, Classification, Adenor...Ahmad Naeem
 
Adrenergic agents
Adrenergic agents Adrenergic agents
Adrenergic agents AymonGhazi
 
Chapter 2 adrenergic agents by somashekhar m metri
Chapter 2 adrenergic agents by somashekhar m metriChapter 2 adrenergic agents by somashekhar m metri
Chapter 2 adrenergic agents by somashekhar m metrisomashekharmetri1
 
Drug Acting on Autonomic nervouse system pdf.pdf
Drug Acting on Autonomic nervouse system pdf.pdfDrug Acting on Autonomic nervouse system pdf.pdf
Drug Acting on Autonomic nervouse system pdf.pdfnamratabaravkar98
 
Adrenergic system
Adrenergic systemAdrenergic system
Adrenergic systemsrinupappu
 
ANS-_Adrenergic_drugs-_Catecholamines.pdf
ANS-_Adrenergic_drugs-_Catecholamines.pdfANS-_Adrenergic_drugs-_Catecholamines.pdf
ANS-_Adrenergic_drugs-_Catecholamines.pdfSanjayaManiDixit
 
1. Neurotransmitter-4-BDS.pptx
1. Neurotransmitter-4-BDS.pptx1. Neurotransmitter-4-BDS.pptx
1. Neurotransmitter-4-BDS.pptxRajendra Dev Bhatt
 
lecture-2 (1) (1).pdf medicinal chemistry-1
lecture-2 (1) (1).pdf medicinal chemistry-1lecture-2 (1) (1).pdf medicinal chemistry-1
lecture-2 (1) (1).pdf medicinal chemistry-1ParmarkevalPravnibha
 
Medicinal Chemistry Unit -2.pptx
Medicinal Chemistry Unit -2.pptxMedicinal Chemistry Unit -2.pptx
Medicinal Chemistry Unit -2.pptxNikita Gupta
 
Neurotransmitters
NeurotransmittersNeurotransmitters
Neurotransmittersvacagodx
 
Autonomic Nervous System
Autonomic Nervous SystemAutonomic Nervous System
Autonomic Nervous SystemJery7
 
Sympathomimetics
SympathomimeticsSympathomimetics
SympathomimeticsKalyaniR5
 
Noradrenergc transmission
Noradrenergc transmissionNoradrenergc transmission
Noradrenergc transmissionamitgajjar85
 
Noradrenergc transmission
Noradrenergc transmissionNoradrenergc transmission
Noradrenergc transmissionamitgajjar85
 
adrenergic agonists & antagonists
adrenergic agonists & antagonistsadrenergic agonists & antagonists
adrenergic agonists & antagonistsdrjawaria73
 
Kenyatta university epinephrine dedermination
Kenyatta university epinephrine dedermination Kenyatta university epinephrine dedermination
Kenyatta university epinephrine dedermination Lando Elvis
 
Drugs Acting on ANS by Aryan Patel
Drugs Acting on ANS by Aryan Patel Drugs Acting on ANS by Aryan Patel
Drugs Acting on ANS by Aryan Patel ARYAN PATEL
 

Similar to 5.adrenergic drugs (20)

Sympathomimetics or Adrenergic Agonists (Introduction, Classification, Adenor...
Sympathomimetics or Adrenergic Agonists (Introduction, Classification, Adenor...Sympathomimetics or Adrenergic Agonists (Introduction, Classification, Adenor...
Sympathomimetics or Adrenergic Agonists (Introduction, Classification, Adenor...
 
Adrenergic agents
Adrenergic agents Adrenergic agents
Adrenergic agents
 
Chapter 2 adrenergic agents by somashekhar m metri
Chapter 2 adrenergic agents by somashekhar m metriChapter 2 adrenergic agents by somashekhar m metri
Chapter 2 adrenergic agents by somashekhar m metri
 
Drug Acting on Autonomic nervouse system pdf.pdf
Drug Acting on Autonomic nervouse system pdf.pdfDrug Acting on Autonomic nervouse system pdf.pdf
Drug Acting on Autonomic nervouse system pdf.pdf
 
Adrenergic system
Adrenergic systemAdrenergic system
Adrenergic system
 
ANS-_Adrenergic_drugs-_Catecholamines.pdf
ANS-_Adrenergic_drugs-_Catecholamines.pdfANS-_Adrenergic_drugs-_Catecholamines.pdf
ANS-_Adrenergic_drugs-_Catecholamines.pdf
 
1. Neurotransmitter-4-BDS.pptx
1. Neurotransmitter-4-BDS.pptx1. Neurotransmitter-4-BDS.pptx
1. Neurotransmitter-4-BDS.pptx
 
lecture-2 (1) (1).pdf medicinal chemistry-1
lecture-2 (1) (1).pdf medicinal chemistry-1lecture-2 (1) (1).pdf medicinal chemistry-1
lecture-2 (1) (1).pdf medicinal chemistry-1
 
Medicinal Chemistry Unit -2.pptx
Medicinal Chemistry Unit -2.pptxMedicinal Chemistry Unit -2.pptx
Medicinal Chemistry Unit -2.pptx
 
Neurotransmitters
NeurotransmittersNeurotransmitters
Neurotransmitters
 
Neurotransmitters
NeurotransmittersNeurotransmitters
Neurotransmitters
 
Neurotransmitter 2
Neurotransmitter 2Neurotransmitter 2
Neurotransmitter 2
 
Autonomic Nervous System
Autonomic Nervous SystemAutonomic Nervous System
Autonomic Nervous System
 
Sympathomimetics
SympathomimeticsSympathomimetics
Sympathomimetics
 
Noradrenergc transmission
Noradrenergc transmissionNoradrenergc transmission
Noradrenergc transmission
 
Noradrenergc transmission
Noradrenergc transmissionNoradrenergc transmission
Noradrenergc transmission
 
Adrenal medulla
Adrenal medullaAdrenal medulla
Adrenal medulla
 
adrenergic agonists & antagonists
adrenergic agonists & antagonistsadrenergic agonists & antagonists
adrenergic agonists & antagonists
 
Kenyatta university epinephrine dedermination
Kenyatta university epinephrine dedermination Kenyatta university epinephrine dedermination
Kenyatta university epinephrine dedermination
 
Drugs Acting on ANS by Aryan Patel
Drugs Acting on ANS by Aryan Patel Drugs Acting on ANS by Aryan Patel
Drugs Acting on ANS by Aryan Patel
 

More from Lama K Banna

The TikTok Masterclass Deck.pdf
The TikTok Masterclass Deck.pdfThe TikTok Masterclass Deck.pdf
The TikTok Masterclass Deck.pdfLama K Banna
 
دليل كتابة المشاريع.pdf
دليل كتابة المشاريع.pdfدليل كتابة المشاريع.pdf
دليل كتابة المشاريع.pdfLama K Banna
 
Investment proposal
Investment proposalInvestment proposal
Investment proposalLama K Banna
 
Lecture 3 facial cosmetic surgery
Lecture 3 facial cosmetic surgery Lecture 3 facial cosmetic surgery
Lecture 3 facial cosmetic surgery Lama K Banna
 
lecture 1 facial cosmatic surgery
lecture 1 facial cosmatic surgery lecture 1 facial cosmatic surgery
lecture 1 facial cosmatic surgery Lama K Banna
 
Facial neuropathology Maxillofacial Surgery
Facial neuropathology Maxillofacial SurgeryFacial neuropathology Maxillofacial Surgery
Facial neuropathology Maxillofacial SurgeryLama K Banna
 
Lecture 2 Facial cosmatic surgery
Lecture 2 Facial cosmatic surgery Lecture 2 Facial cosmatic surgery
Lecture 2 Facial cosmatic surgery Lama K Banna
 
Lecture 12 general considerations in treatment of tmd
Lecture 12 general considerations in treatment of tmdLecture 12 general considerations in treatment of tmd
Lecture 12 general considerations in treatment of tmdLama K Banna
 
Lecture 10 temporomandibular joint
Lecture 10 temporomandibular jointLecture 10 temporomandibular joint
Lecture 10 temporomandibular jointLama K Banna
 
Lecture 11 temporomandibular joint Part 3
Lecture 11 temporomandibular joint Part 3Lecture 11 temporomandibular joint Part 3
Lecture 11 temporomandibular joint Part 3Lama K Banna
 
Lecture 9 TMJ anatomy examination
Lecture 9 TMJ anatomy examinationLecture 9 TMJ anatomy examination
Lecture 9 TMJ anatomy examinationLama K Banna
 
Lecture 7 correction of dentofacial deformities Part 2
Lecture 7 correction of dentofacial deformities Part 2Lecture 7 correction of dentofacial deformities Part 2
Lecture 7 correction of dentofacial deformities Part 2Lama K Banna
 
Lecture 8 management of patients with orofacial clefts
Lecture 8 management of patients with orofacial cleftsLecture 8 management of patients with orofacial clefts
Lecture 8 management of patients with orofacial cleftsLama K Banna
 
Lecture 5 Diagnosis and management of salivary gland disorders Part 2
Lecture 5 Diagnosis and management of salivary gland disorders Part 2Lecture 5 Diagnosis and management of salivary gland disorders Part 2
Lecture 5 Diagnosis and management of salivary gland disorders Part 2Lama K Banna
 
Lecture 6 correction of dentofacial deformities
Lecture 6 correction of dentofacial deformitiesLecture 6 correction of dentofacial deformities
Lecture 6 correction of dentofacial deformitiesLama K Banna
 
lecture 4 Diagnosis and management of salivary gland disorders
lecture 4 Diagnosis and management of salivary gland disorderslecture 4 Diagnosis and management of salivary gland disorders
lecture 4 Diagnosis and management of salivary gland disordersLama K Banna
 
Lecture 3 maxillofacial trauma part 3
Lecture 3 maxillofacial trauma part 3Lecture 3 maxillofacial trauma part 3
Lecture 3 maxillofacial trauma part 3Lama K Banna
 
Lecture 2 maxillofacial trauma
Lecture 2 maxillofacial traumaLecture 2 maxillofacial trauma
Lecture 2 maxillofacial traumaLama K Banna
 

More from Lama K Banna (20)

The TikTok Masterclass Deck.pdf
The TikTok Masterclass Deck.pdfThe TikTok Masterclass Deck.pdf
The TikTok Masterclass Deck.pdf
 
دليل كتابة المشاريع.pdf
دليل كتابة المشاريع.pdfدليل كتابة المشاريع.pdf
دليل كتابة المشاريع.pdf
 
Investment proposal
Investment proposalInvestment proposal
Investment proposal
 
Funding proposal
Funding proposalFunding proposal
Funding proposal
 
5 incisions
5 incisions5 incisions
5 incisions
 
Lecture 3 facial cosmetic surgery
Lecture 3 facial cosmetic surgery Lecture 3 facial cosmetic surgery
Lecture 3 facial cosmetic surgery
 
lecture 1 facial cosmatic surgery
lecture 1 facial cosmatic surgery lecture 1 facial cosmatic surgery
lecture 1 facial cosmatic surgery
 
Facial neuropathology Maxillofacial Surgery
Facial neuropathology Maxillofacial SurgeryFacial neuropathology Maxillofacial Surgery
Facial neuropathology Maxillofacial Surgery
 
Lecture 2 Facial cosmatic surgery
Lecture 2 Facial cosmatic surgery Lecture 2 Facial cosmatic surgery
Lecture 2 Facial cosmatic surgery
 
Lecture 12 general considerations in treatment of tmd
Lecture 12 general considerations in treatment of tmdLecture 12 general considerations in treatment of tmd
Lecture 12 general considerations in treatment of tmd
 
Lecture 10 temporomandibular joint
Lecture 10 temporomandibular jointLecture 10 temporomandibular joint
Lecture 10 temporomandibular joint
 
Lecture 11 temporomandibular joint Part 3
Lecture 11 temporomandibular joint Part 3Lecture 11 temporomandibular joint Part 3
Lecture 11 temporomandibular joint Part 3
 
Lecture 9 TMJ anatomy examination
Lecture 9 TMJ anatomy examinationLecture 9 TMJ anatomy examination
Lecture 9 TMJ anatomy examination
 
Lecture 7 correction of dentofacial deformities Part 2
Lecture 7 correction of dentofacial deformities Part 2Lecture 7 correction of dentofacial deformities Part 2
Lecture 7 correction of dentofacial deformities Part 2
 
Lecture 8 management of patients with orofacial clefts
Lecture 8 management of patients with orofacial cleftsLecture 8 management of patients with orofacial clefts
Lecture 8 management of patients with orofacial clefts
 
Lecture 5 Diagnosis and management of salivary gland disorders Part 2
Lecture 5 Diagnosis and management of salivary gland disorders Part 2Lecture 5 Diagnosis and management of salivary gland disorders Part 2
Lecture 5 Diagnosis and management of salivary gland disorders Part 2
 
Lecture 6 correction of dentofacial deformities
Lecture 6 correction of dentofacial deformitiesLecture 6 correction of dentofacial deformities
Lecture 6 correction of dentofacial deformities
 
lecture 4 Diagnosis and management of salivary gland disorders
lecture 4 Diagnosis and management of salivary gland disorderslecture 4 Diagnosis and management of salivary gland disorders
lecture 4 Diagnosis and management of salivary gland disorders
 
Lecture 3 maxillofacial trauma part 3
Lecture 3 maxillofacial trauma part 3Lecture 3 maxillofacial trauma part 3
Lecture 3 maxillofacial trauma part 3
 
Lecture 2 maxillofacial trauma
Lecture 2 maxillofacial traumaLecture 2 maxillofacial trauma
Lecture 2 maxillofacial trauma
 

Recently uploaded

Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAkashGanganePatil1
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)Monika Kanwar
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxSergio Pinski
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Dr. Aryan (Anish Dhakal)
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feeldranji1
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentabdeli bhadarva
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryDr Simran Deepak Vangani
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfDr Jeenal Mistry
 
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdfKs doctor
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...Catherine Liao
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyDr KHALID B.M
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadNephroTube - Dr.Gawad
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxgauripg8
 
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...kevinkariuki227
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesTina Purnat
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxgauripg8
 
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLSlakehe2738
 
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Catherine Liao
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxDr KHALID B.M
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 

Recently uploaded (20)

Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feel
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
 
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
 
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLS
 
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 

5.adrenergic drugs

  • 1. Dr. Mahmoud H. Taleb Assistant Professor of Pharmacology and Toxicology Head of Department of Pharmacology and Medical Sciences, Faculty of Pharmacy- Al azhar University The Autonomic Nervous System Adrenergic SystemAdrenergic System
  • 2. • Adrenergic neurons release norepinephrine as the primary neurotransmitter. • These neurons are found in the central nervous system (CNS) and also in the sympathetic nervous system, where they serve as links between ganglia and the effector organs. • The adrenergic neurons and receptors, located either presynaptically on the neuron or postsynaptically on the effector organ, are the sites of action of the adrenergic drugs. THE ADRENERGIC NEURON
  • 3. 2- Sympathetic nervouS SyStem  Sympathetic Nervous System (adrenergic) Norepinephrine = neurotransmitter - Drugs that mimic = adrenergic drugs, sympathomimetics, or adrenomemetics * Adrenergic agonists - Drugs initiate a response - Drugs that block = adrenergic blockers, sympatholytics or adrenolytics * Adrenergic antagonists - prevent a response Dr. Mahmoud H. Taleb 3
  • 4. Dr. Mahmoud H. Taleb 4 Adrenergic Agonists The adrenergic drugs affect receptors that are stimulated by norepinephrine or epinephrine. Some adrenergic drugs act directly on the adrenergic receptor (adrenoceptor) by activating it and are said to be sympathomimetic. Others, which will be dealt with in, block the action of the neurotransmitters at the receptors (sympatholytics), .
  • 5.
  • 6. Agonist affinity of α : -Adrenalin < Noradrenalin < isoproterenol -Antagonist : phenoxybenzamine -IP3/DAG , cAMP ↓and k+ channel opening. Agonist affinity of β : -Iso < Adrenalin < Noradrenalin -Propraolol -cAMP and Ca +2 channel opening.
  • 7. Where are the adrenergic receptors?
  • 8. Dr. Mahmoud H. Taleb 8
  • 9. -D1-receptors are postsynaptic receptors located in blood vessels and CNS. - D2-receptors are presynaptic present in CNS , ganglia, renal cortex.
  • 10. SYNTHESIS AND RELEASE OF NOREPINEPHRINE FROM THE ADRENERGIC NEURON
  • 11. 1. The amino acid tyrosine is transported into the sympathetic nerve axon. 2. Tyrosine (Tyr) is converted to DOPA by tyrosine hydroxylase (rate-limiting step for NE synthesis). 3. DOPA is converted to dopamine (DA) by DOPA decarboxylase. 4. Dopamine is transported into vesicles then converted to norepinephrine (NE) by dopamine β- hydroxylase (DBH); transport into the vesicle can by blocked by the drug reserpine. 5. An action potential traveling down the axon depolarizes the membrane and causes calcium to enter the axon. 6. Increased intracellular calcium causes the vesicles to migrate to the axonal membrane and fuse with the membrane, which permits the NE to diffuse out of the vesicle into the extracellular (junctional) space. DBH, and depending on the nerve other secondary neurotransmitters (e.g., ATP), is released along with the NE. 7. The NE binds to the postjunctional receptor and stimulates the effector organ response
  • 12.
  • 13. 1. Most (~90%) of the NE is transported back into the nerve terminal by a neuronal reuptake transport system. This transporter is blocked by cocaine; therefore, cocaine increases junctional NE concentrations by blocking its reuptake and subsequent metabolism. (This is a major mechanism by which cocaine stimulates cardiac function and raises blood pressure.) 2. Some of the junctional NE diffuses into capillaries and is carried out of the tissue by the circulation. Therefore, high levels of sympathetic activation in the body increase the plasma concentration of NE and its metabolites. 3. Some of the junctional NE is metabolized within the extracellular space before reaching the capillaries. 4. A small amount of NE (~5%) is taken up by the postjunctional tissue (termed "extraneuronal uptake") and metabolized.
  • 14. NE (and epinephrine) is metabolized by catechol-O- methytransferase (COMT) and monoamine oxidase (MAO). The final product of these pathways is vanillylmandelic acid (VMA). This final product, along with its precursors normetanephrine and metanephrine, is measured in urine and plasma in the diagnosis of pheochromocytoma, which can cause severe hypertension and cardiac arrhythmias.
  • 15. Dr. Mahmoud H. Taleb 15
  • 16.
  • 17. • Sympathomimetic amines that contain the 3,4-dihydroxybenzene group: (such as epinephrine, norepinephrine, isoproterenol, and dopamine) are called catecholamines. • These compounds share the following properties: 1. High potency 2. Rapid inactivation 3. Poor penetration into the CNS
  • 18. Dr. Mahmoud H. Taleb 18 A. Catecholamines Sympathomimetic amines that contain the 3,4-dihydroxybenzene group (such as epinephrine, norepinephrine, isoproterenol, and dopamine) are called catecholamines. These compounds share the following properties: High potency: Drugs that are catechol derivatives (with OH groups in the 3 and 4 positions on the benzene ring) show the highest potency in directly activating α or β receptors Rapid inactivation: Not only are the catecholamines metabolized by COMT postsynaptically and by MAO intraneuronally, they are also metabolized in other tissues. For example, COMT is in the gut wall, and MAO is in the liver and gut wall. Thus, catecholamines have only a brief period of action when given parenterally, and they are ineffective when administered orally because of inactivation2. Poor penetration into the CNS: Catecholamines are polar and, therefore, do not readily penetrate into the CNS. Nevertheless, most of these drugs have some clinical effects (anxiety, tremor, and headaches) that are attributable to action on the CNS.
  • 19. Dr. Mahmoud H. Taleb 19 B. Noncatecholamines Compounds lacking the catechol hydroxyl groups have longer half-lives, because they are not inactivated by COMT. These include phenylephrine, ephedrine, and amphetamine. Phenylephrine, an analog of epinephrine, has only a single OH at position 3 on the benzene ring, whereas ephedrine lacks hydroxyls on the ring but has a methyl substitution at the α-carbon. These are poor substrates for MAO and, thus, show a prolonged duration of action, because MAO is an important route of detoxification. Increased lipid solubility of many of the noncatecholamines permits greater access to the CNS.
  • 20. • Compounds lacking the catechol hydroxyl groups have longer half-lives, because they are not inactivated by COMT. • These include:  phenylephrine,  ephedrine, and  amphetamine.
  • 21.
  • 22.
  • 23. • Epinephrine is synthesized from tyrosine in the adrenal medulla and released, along with small quantities of norepinephrine, into the bloodstream. • Epinephrine interacts with both α and β receptors. • At low doses, β effects (vasodilation) on the vascular system predominate, whereas at high doses, α effects (vasoconstriction) are strongest.
  • 24. • Adrenaline is a catecholamine, produced only by the adrenal glands from the amino acid, phenylalanine and tyrosine. That acts as both a neurotransmitter and hormone is also known as (epinephrine). • Adrenaline is produced in the medulla of the adrenal glands and in some neurons of the central nervous system. They are released into the bloodstream and serve as chemical mediators, and also convey the nerve impulses to various organs.
  • 25. Adrenaline has many different actions depending on the type of cells it is acting upon. However, the overall effect of adrenaline is to prepare the body for the ‘fight or flight’ response in times of stress, i.e., for vigorous and/or sudden action. Key actions of adrenaline include increasing the heart rate, increasing blood pressure, expanding the air passages of the lungs, enlarging the pupil in the eye (mydriasis), redistributing blood to the muscles and altering the body’s metabolism, so as to maximise blood glucose levels (primarily for the brain). Adrenaline interacts with both α and β receptors. At low doses, β effects (vasodilation) on the vascular system predominate, whereas at high doses, α effects (vasoconstriction) are the strongest.
  • 26. CARDIOVASCULAR RESPIRATORY HYPERGLYCEMIA LIPOLYSIS Epinephrine strengthens the contractility of the myocardium (positive inotropic: β1 action) and increases its rate of contraction (positive chronotropic: β1 action). Epinephrine causes powerful bronchodilation by acting directly on bronchial smooth muscle (β2 action). Epinephrine has a significant hyperglycemic effect because of increased glycogenolysis in the liver (β2 effect), increased release of glucagon (β2 effect), and a decreased release of insulin (α2 effect). Epinephrine initiates lipolysis through its agonist activity on the β receptors of adipose tissue, which upon stimulation activate adenylyl cyclase to increase cAMP levels.
  • 27. •ACTIONS OF ADRENALINE • HERT : • Beta-1 mediated action - Powerful Cardiac stimulant ( +ve chronotropic, +ve inotropic) • Acts on beta-1 receptors in myocardium, pacemaker cells and conducting tissue – Heart rate increases by increasing slow diastolic depolarization of cells in SAN – High doses cause marked rise in heart rate and BP causing reflex depression of SAN – unmasking of latent pacemaker cells in AVN and PF – arrhythmia. – Cardiac systole is shorter and more powerful – Cardiac output is enhanced and Oxygen consumption is increased – Cardiac efficiency is markedly decreased • Conduction velocity in AVN, atrial muscle fiber, ventricular fibre and Bundle of His increased – benefit in partial AV block – Reduced refractory period in all cardiac cells •
  • 28. • Blood Vessels : • Seen mainly in the smaller vessels – arterioles – Vasoconstriction (alpha) and vasodilatation (beta) . • Decreased blood flow to skin and mucus membranes and renal beds – alpha effect (1 and 2) • Increased blood flow to skeletal muscles, coronary and liver vessels - (Beta-2 effect) counterbalanced by vasoconstrictor effect of alpha receptors. • 
  • 29. • Respiratory : – Powerful bronchodilator – Relaxes bronchial smooth muscle (not NA) • Beta-2 mediated effect • Physiological antagonist to mediators of bronchoconstriction e.g. Histamine
  • 30. • GIT : • Relaxation of gut muscles (alpha and beta effect) and constricted sphincters – reduced peristalsis – not clinical importance.
  • 31. • Uterus : • Adrenaline contracts and relaxes Uterus (alpha and beta action) but net effect depends on status of uterus and species – pregnant relaxes but non-pregnant – contracts. • Skeletal Muscle : – Facilitation of Ach release in NM junction (α -1). – Beta-2 acts directly on Muscle fibres. – Abbreviated active state and less tension in slow conducting fibres and enhanced muscle spindle firing – tremor.
  • 32. • Hyperglycemia : • Epinephrine has a significant hyperglycemic effect because of increased glycogenolysis in the liver (β2 effect),increased release of glucagon (β2 effect), and a decreased release of insulin (α2 effect). • Lipolysis : • Epinephrine initiates lipolysis through agonist activity on the β receptors of adipose tissue. Increased levels of cAMP stimulate a hormone-sensitive lipase, which hydrolyzes triglycerides to free fatty acids and glycerol.
  • 33. • Metabolic effects : • Increases concentration of glucose and lactic acid • Calorigenesis (β-2 and β-3) • Inhibits insulin secretion (α-2) • Decreases uptake of glucose by peripheral tissue • Simulates glycogenolysis - Beta effect • Increases free fatty acid concentration in blood • Hypokalemia – initial hyperkalemia
  • 34. BRONCHOSPASM GLAUCOMA ANAPHYLACTIC SHOCK CARDIAC ARREST ANESTHETICS Epinephrine is the primary drug used in the emergency treatment of any condition of the respiratory tract when bronchoconstriction has resulted in diminished respiratory exchange. In ophthalmology, a two-percent epinephrine solution may be used topically to reduce intraocular pressure in open- angle glaucoma. Epinephrine is the drug of choice for the treatment of Type I hypersensitivity reactions in response to allergens. Epinephrine may be used to restore cardiac rhythm in patients with cardiac arrest regardless of the cause. The effect of the drug is to greatly increase the duration of the local anesthesia.
  • 35. • Because norepinephrine is the neuromediator of adrenergic nerves, it should theoretically stimulate all types of adrenergic receptors. • In practice, when the drug is given in therapeutic doses to humans, the α- adrenergic receptor is most affected.
  • 36. VASOCONSTRICTION BARORECEPTOR REFLEX EFFECTS OF ATROPINE PRE- TREATMENT Norepinephrine causes a rise in peripheral resistance due to intense vasoconstriction of most vascular beds, including the kidney (α1 effect). In isolated cardiac tissue, norepinephrine stimulates cardiac contractility; however, in vivo, little if any cardiac stimulation is noted. If atropine, which blocks the transmission of vagal effects, is given before norepinephrine, then norepinephrine stimulation of the heart is evident as tachycardia.
  • 37. • Isoproterenol is a direct-acting synthetic catecholamine that predominantly stimulates both β1- and β2-adrenergic receptors. • Its nonselectivity is one of its drawbacks and the reason why it is rarely used therapeutically. • Its action on α receptors is insignificant.
  • 38. CARDIOVASCULAR PULMONARY OTHER EFFECTS Isoproterenol produces intense stimulation of the heart to increase its rate and force of contraction, causing increased cardiac output. Isoproterenol is as active as epinephrine and rapidly alleviates an acute attack of asthma when taken by inhalation (which is the recommended route). Other actions on β receptors, such as increased blood sugar and increased lipolysis, can be demonstrated but are not clinically significant.
  • 39. • Dopamine, the immediate metabolic precursor of norepinephrine, occurs naturally in the CNS in the basal ganglia, where it functions as a neurotransmitter, as well as in the adrenal medulla. • Dopamine can activate α- and β-adrenergic receptors.
  • 40. CARDIOVASCULAR RENAL & VISCERAL Dopamine exerts a stimulatory effect on the β1 receptors of the heart, having both inotropic and chronotropic effects. Dopamine dilates renal and splanchnic arterioles by activating dopaminergic receptors, thus increasing blood flow to the kidneys and other viscera. Therefore, dopamine is clinically useful in the treatment of shock, in which significant increases in sympathetic activity might compromise renal function.
  • 41. • Dobutamine is a synthetic, direct-acting catecholamine that is a β1-receptor agonist. • One of the stereoisomers has a stimulatory activity. • It increases cardiac rate and output with few vascular effects. • Dobutamine is used to increase cardiac output in congestive heart failure as well as for inotropic support after cardiac surgery.
  • 42. • Oxymetazoline is a direct-acting synthetic adrenergic agonist that stimulates both α1- and α2-adrenergic receptors. • It is primarily used locally in the eye or the nose as a vasoconstrictor. • Oxymetazoline is found in many over- the-counter short-term nasal spray decongestant products as well as in ophthalmic drops for the relief of redness of the eyes associated with swimming, colds, or contact lens.
  • 43. • Phenylephrine is a direct-acting, synthetic adrenergic drug that binds primarily to α receptors and favors α1 receptors over α2 receptors. • It is not a catechol derivative and, therefore, not a substrate for COMT. • Phenylephrine is a vasoconstrictor that raises both systolic and diastolic blood pressures.
  • 44. • Methoxamine is a direct-acting, synthetic adrenergic drug that binds primarily to α-receptors, with α1 receptors favored over α2 receptors. • Methoxamine raises blood pressure by stimulating α1 receptors in the arterioles, causing vasoconstriction. • This causes an increase in total peripheral resistance.
  • 45. • Clonidine is an α2 agonist that is used in essential hypertension to lower blood pressure because of its action in the CNS. • It can be used to minimize the symptoms that accompany withdrawal from opiates or benzodiazepines. • Clonidine acts centrally to produce inhibition of sympathetic vasomotor centers, decreasing sympathetic outflow to the periphery.
  • 46. • Albuterol, pirbuterol, and terbutaline are short- acting β2 agonists used primarily as bronchodilators and administered by a metered-dose inhaler.
  • 47. • Salmeterol and formoterol are β2-adrenergic selective, long- acting bronchodilators. • Salmeterol and formoterol are the agents of choice for treating nocturnal asthma in symptomatic patients taking other asthma medications.
  • 48.
  • 49. • The marked central stimulatory action of amphetamine is often mistaken by drug abusers as its only action. • The CNS stimulant effects of amphetamine and its derivatives have led to their use for treating hyperactivity in children, narcolepsy, and appetite control. • Its use in pregnancy should be avoided because of adverse effects on development of the fetus.
  • 50. • Tyramine is not a clinically useful drug, but it is important because it is found in fermented foods, such as ripe cheese and Chianti wine. • It is a normal by-product of tyrosine metabolism. • Normally, it is oxidized by MAO in the gastrointestinal tract, but if the patient is taking MAO inhibitors, it can precipitate serious vasopressor episodes.
  • 51. • Cocaine is unique among local anesthetics in having the ability to block the Na+ /K+ -activated ATPase (required for cellular uptake of norepinephrine) on the cell membrane of the adrenergic neuron. • Like amphetamines, it can increase blood pressure by α-agonist actions and β-stimulatory effects.
  • 52.
  • 53. • Ephedrine, and pseudoephedrine are plant alkaloids, that are now made synthetically. • These drugs are mixed-action adrenergic agents. • They not only release stored norepinephrine from nerve endings but also directly stimulate both α and β receptors. • Thus, a wide variety of adrenergic actions ensue that are similar to those of epinephrine, although less potent.
  • 54. • Ephedrine enhances contractility and improves motor function in myasthenia gravis. • Ephedrine has been used to treat asthma, as a nasal decongestant (due to its local vasoconstrictor action), and to raise blood pressure. • Pseudoephedrine is primarily used to treat nasal and sinus congestion or congestion of the eustachian tubes.
  • 55. Dr. Mahmoud H. Taleb 55